Protara Therapeutics Inc
NASDAQ:TARA
Balance Sheet
Balance Sheet Decomposition
Protara Therapeutics Inc
Protara Therapeutics Inc
Balance Sheet
Protara Therapeutics Inc
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
2
|
3
|
69
|
40
|
36
|
21
|
19
|
6
|
169
|
36
|
24
|
40
|
163
|
|
| Cash Equivalents |
2
|
3
|
69
|
40
|
36
|
21
|
19
|
6
|
169
|
36
|
24
|
40
|
163
|
|
| Short-Term Investments |
5
|
2
|
15
|
25
|
5
|
21
|
3
|
0
|
0
|
56
|
60
|
26
|
7
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
3
|
2
|
|
| Total Current Assets |
8
|
5
|
85
|
67
|
43
|
44
|
23
|
7
|
169
|
93
|
86
|
69
|
172
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
8
|
7
|
5
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
8
|
7
|
5
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
30
|
30
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
40
|
18
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
4
|
4
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
30
|
30
|
0
|
0
|
0
|
|
| Total Assets |
8
N/A
|
6
-27%
|
85
+1 388%
|
68
-20%
|
44
-36%
|
44
+1%
|
24
-47%
|
7
-70%
|
203
+2 803%
|
173
-15%
|
113
-34%
|
79
-30%
|
181
+130%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
1
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
4
|
|
| Accrued Liabilities |
1
|
1
|
1
|
3
|
5
|
9
|
3
|
0
|
2
|
3
|
4
|
4
|
7
|
|
| Short-Term Debt |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
5
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
10
|
2
|
4
|
5
|
9
|
3
|
1
|
3
|
4
|
6
|
6
|
11
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
6
|
6
|
4
|
3
|
|
| Total Liabilities |
4
N/A
|
10
+133%
|
2
-77%
|
4
+78%
|
5
+24%
|
9
+80%
|
3
-66%
|
1
-81%
|
4
+550%
|
11
+174%
|
11
+5%
|
11
-5%
|
14
+35%
|
|
| Equity | ||||||||||||||
| Common Stock |
90
|
96
|
0
|
0
|
0
|
22
|
22
|
19
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
87
|
101
|
110
|
131
|
160
|
190
|
211
|
226
|
47
|
94
|
160
|
200
|
245
|
|
| Additional Paid In Capital |
0
|
0
|
192
|
195
|
198
|
203
|
209
|
213
|
246
|
256
|
263
|
269
|
412
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
4
N/A
|
4
N/A
|
83
N/A
|
63
-23%
|
38
-39%
|
35
-10%
|
20
-41%
|
6
-69%
|
199
+3 013%
|
162
-19%
|
102
-37%
|
68
-33%
|
167
+145%
|
|
| Total Liabilities & Equity |
8
N/A
|
6
-27%
|
85
+1 388%
|
68
-20%
|
44
-36%
|
44
+1%
|
24
-47%
|
7
-70%
|
203
+2 803%
|
173
-15%
|
113
-34%
|
79
-30%
|
181
+130%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
11
|
11
|
11
|
11
|
35
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|